Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effectiveness of flexible doses (15-30mg) of Aripiprazole in the treatment of patients with schizophrenia and co-morbid symptoms of OCD in the outpatient setting. The overall effectiveness of Aripiprazole will be evaluated by use of the Brief Psychiatric Rating Scale(BPRS), Yale-Brown OCD scale and Clinical Global Impression-Improvement(CGI-I) scale.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jamaica Hospital Medical Center
• Collaborators: Bristol-Myers Squibb; Department of Psychiatry, Jamaica Hospital Medical Center; Research Division
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Man and Women 18-65 years of age.

• Patients who are capable of giving Informed Consent and fluent in English.

• Patients who have DSM IV -Diagnosis of schizophrenia with co-morbid OCD symptoms and BPRS score averaging from mild to moderate (3-4).

• Patients whose obsessive symptoms are not optimally controlled and require a change of treatment.YBOCS score of more than 16.

Exclusion Criteria:

• Outside the age range of 18-65 years.

• Patients with current evidence(past three months) of substance abuse.

• Women of child bearing age who are unwilling to use acceptable methods of contraception.

• Patients who have had recent treatment with long-acting antipsychotic.

• Patients who are suicidal or who have history of recent suicidal attempt.

• History of significant medical condition e.g. seizures, cardiovascular, endocrine,gastrointestinal,renal or respiratory diseases.